keyword
MENU ▼
Read by QxMD icon Read
search

Discontinuation of chemotherapy treatment

keyword
https://www.readbyqxmd.com/read/28213365/fda-approval-summary-tas-102
#1
Leigh Marcus, Steven J Lemery, Sachia Khasar, Emily Wearne, Whitney S Helms, Weishi Yuan, Kun He, Xianhua Cao, Jingyu Yu, Hong Zhao, Yaning Wang, Olen Stephens, Erika Englund, Rajiv Agarwal, Patricia Keegan, Richard Pazdur
FDA approved TAS-102 (Lonsurf, Taiho Oncology, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In an international, multicenter, double-blinded, placebo-controlled trial (TPU-TAS-102-301, herein referred to as RECOURSE), 800 patients with previously treated mCRC were randomly allocated (2:1) to receive either TAS-102 35mg/m2 orally twice daily after meals on Days 1-5 and 8-12 of each 28-day cycle (n=534) or matching placebo (n=266)...
February 17, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28204996/incidence-of-taxane-induced-peripheral-neuropathy-receiving-treatment-and-prescription-patterns-in-patients-with-breast-cancer
#2
Su Jeong Song, Ji Min, Sung Yun Suh, Sun Hoi Jung, Hyeon Joo Hahn, Seock-Ah Im, Ju-Yeun Lee
PURPOSE: Taxane-induced peripheral neuropathy (TIPN) can affect quality of life and treatment outcomes in breast cancer patients. Despite the high incidence, treatment of PN has not been established. This study aimed to evaluate the incidence, risk factors, and prescribing pattern of TIPN receiving pharmacologic treatment in real-world practice. METHODS: We conducted a retrospective chart review of 1629 breast cancer patients who received taxanes at the Seoul National University Hospital from July 2012 to June 2014...
February 16, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28204914/salvage-therapy-with-bendamustine-for-temozolomide-refractory-recurrent-anaplastic-gliomas-a-prospective-phase-ii-trial
#3
Marc C Chamberlain, Howard Colman, Bryan T Kim, Jeffrey Raizer
There is no standard therapy for recurrent anaplastic glioma (AG). Salvage therapies include alkylator-based chemotherapy, re-resection with or without carmustine implants, re-irradiation and bevacizumab. Bendamustine is a novel bifunctional alkylator with CNS penetration never previously evaluated in AG. Assess response and toxicity of bendamustine in recurrent AG in a phase II trial. Adults with radiation and temozolomide refractory recurrent AG were treated with bendamustine. A cycle of bendamustine was defined as two consecutive days of treatment (100 mg/m(2)/day) administered once every 4 weeks...
February 16, 2017: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/28203409/practice-patterns-in-venous-thromboembolism-vte-prophylaxis-in-thoracic-surgery-a-comprehensive-canadian-delphi-survey
#4
John Agzarian, Lori-Ann Linkins, Laura Schneider, Waël C Hanna, Christian J Finley, Colin Schieman, Marc De Perrot, Mark Crowther, James Douketis, Yaron Shargall
BACKGROUND: The incidence of venous thromboembolic events (VTE) after resection of thoracic malignancies can reach 15%, but prophylaxis guidelines are yet to be established. We aimed to survey Canadian practitioners regarding perioperative risk factors for VTE, impact of those factors on extended prophylaxis selection, type of preferred prophylaxis, and timing of initiation and duration of thromboprophylaxis. METHODS: A modified Delphi survey was undertaken over three rounds with thoracic surgeons, thoracic anesthesiologists and thrombosis experts across Canada...
January 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28203175/ibrutinib-is-effective-in-the-treatment-of-autoimmune-haemolytic-anaemia-in-mantle-cell-lymphoma
#5
Aliénor Galinier, Vincent Delwail, Mathieu Puyade
Autoimmune haemolytic anaemia (AIHA) in mantle cell lymphoma (MCL) is a rare but life-threatening complication. To date, there are no relevant data for treatment of AIHA in MCL. Ibrutinib, which has been approved for relapse/refractory MCL, is an immunomodulatory drug inhibiting Th2 activation and consequently the production of autoantibodies. We report a case of MCL with AIHA in which this form of anaemia was not controlled with the usual chemotherapy. Ibrutinib was used when MCL with AIHA relapsed, and it allowed rapid remission of AIHA and rapid discontinuation of steroid therapy...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28196674/cost-effectiveness-analysis-of-dose-dense-versus-standard-intravenous-chemotherapy-for-ovarian-cancer-an-economic-analysis-of-results-from-the-gynecologic-oncology-group-protocol-262-randomized-controlled-trial
#6
Brandon-Luke L Seagle, Shohreh Shahabi
OBJECTIVES: To determine the cost-effectiveness of dose-dense versus standard intravenous adjuvant chemotherapy for ovarian cancer using results from the no-bevacizumab cohort of the Gynecologic Oncology Group protocol 262 (GOG-262) randomized controlled trial, which reported a smaller absolute progression-free survival (PFS) benefit than the prior Japanese trial. METHODS: A three-state Markov decision model from a healthcare system perspective with a 21day cycle length and 28month time-horizon was used to calculate incremental cost-effectiveness ratio (ICER) values per progression-free life-year saved (PFLYS) using results from GOG-262...
February 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28196257/association-between-use-of-a-scalp-cooling-device-and-alopecia-after-chemotherapy-for-breast-cancer
#7
Hope S Rugo, Paula Klein, Susan Anitra Melin, Sara A Hurvitz, Michelle E Melisko, Anne Moore, Glen Park, Jules Mitchel, Erika Bågeman, Ralph B D'Agostino, Elizabeth S Ver Hoeve, Laura Esserman, Tessa Cigler
Importance: Chemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited. Objectives: To evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes in quality of life. Design, Setting, and Participants: A prospective cohort study conducted at 5 US medical centers of women with stage I or II breast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential or combination anthracycline and taxane (106 patients in the scalp cooling group and 16 in the control group; 14 matched by both age and chemotherapy regimen)...
February 14, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28191295/small-cell-carcinoma-of-the-prostate-in-an-elderly-patient-a-case-report-and-review-of-the-literature
#8
Dale Alan Whitaker, Daniel H Miller, Niveditha Jagadesh, Gerald W Strong, Lauren Hintenlang, William B Schenk, Gregory A Broderick, Katherine S Tzou, Steven J Buskirk
Prostate cancer is the most common malignancy of men in the United States. Small-cell carcinoma (SCC), which typically presents as an aggressive lung malignancy, is a rare diagnosis within the setting of prostate cancer pathology. Due to its limited prevalence, little information regarding the treatment and prognosis of this disease in large populations is available. To date our current knowledge base is largely limited to case reports and retrospective case reviews. The mainstay of treatment for this particular histology most often involves a multimodality approach utilizing chemotherapy in conjunction with radiation therapy, androgen deprivation therapy, or prostatectomy...
November 17, 2016: Rare Tumors
https://www.readbyqxmd.com/read/28183144/rapid-deterioration-of-latent-hbv-hepatitis-during-cushing-disease-and-posttraumatic-stress-disorder-after-earthquake
#9
Ryosuke Tashiro, Yoshikazu Ogawa, Teiji Tominaga
Reactivation of the hepatitis B virus (HBV) is a risk in the 350 million HBV carriers worldwide. HBV reactivation may cause hepatocellular carcinoma, cirrhosis, and fulminant hepatitis, and HBV reactivation accompanied with malignant tumor and/or chemotherapy is a critical problem for patients with chronic HBV infection. Multiple risk factors causing an immunosuppressive state can also induce HBV reactivation.We present a case of HBV reactivation during an immunosuppressive state caused by Cushing disease and physical and psychological stress after a disaster...
February 9, 2017: Journal of Neurological Surgery. Part A, Central European Neurosurgery
https://www.readbyqxmd.com/read/28177095/-atypical-hemolytic-uremic-syndrome-related-to-oxalyplatin-cancer-chemotherapy-responsive-to-eculizumab
#10
Fulvia Zanchelli, Elena Tampieri, Francesco Gozzetti, Mattia Monti, Davide Martelli, Romina Graziani, Eliana Zuffa, Daniele Vincenzi, Alessandro Gamboni, Andrea Buscaroli
We describe the case of a patient with adenocarcinoma of the colon treated with FOLFOX-4 (5-Fluorouracil, Folinic acid, Oxalyplatin), with subsequent appearance of atypical hemolytic uremic syndrome (aHUS). From 1999 to 2009, 13 cases of atypical HUS receiving chemotherapy with oxaliplatin have been described, as well as some sporadic cases. None of these cases has been treated with eculizumab. This is the first report of a patient with aHUS secondary to Oxalyplatin treated with Eculizumab. This treatment induced a complete remission of the syndrome and, later on, it has been discontinued with clinical and laboratory permanent remission...
January 2017: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://www.readbyqxmd.com/read/28167659/targeting-btk-with-ibrutinib-in-relapsed-refractory-marginal-zone-lymphoma
#11
Ariela Noy, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher R Flowers, Franck Morschhauser, Graham P Collins, Shuo Ma, Morton Coleman, Shachar Peles, Stephen Smith, Jacqueline C Barrientos, Alina Smith, Brian Munneke, Isaiah Dimery, Darrin M Beaupre, Robert Chen
Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no standard treatment exists. MZL is frequently linked to chronic infection, which may induce B-cell receptor (BCR) signaling resulting in aberrant B-cell survival and proliferation. We conducted a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of ibrutinib in previously treated MZL. Patients with histologically-confirmed MZL of all subtypes who received ≥1 prior therapy with an anti-CD20 antibody-containing regimen were treated with ibrutinib 560 mg orally once daily until progression or unacceptable toxicity...
February 6, 2017: Blood
https://www.readbyqxmd.com/read/28160544/effects-of-hypericum-perforatum-extract-on-oxaliplatin-induced-neurotoxicity-in-vitro-evaluations
#12
Lorenzo Cinci, Lorenzo Di Cesare Mannelli, Anna Maidecchi, Luisa Mattoli, Carla Ghelardini
Hypericum perforatum L. has been used for centuries as a natural remedy for the treatment of many disorders. Neuropathic pain is a common side effect of oxaliplatin-based chemotherapy and often the cause of therapy discontinuation. Thanks to its anti-inflammatory and analgesic effects, the use of H. perforatum may be a novel therapeutic strategy for neuropathy. The aim of this paper was to evaluate the effect of H. perforatum hydrophilic extract on an in vitro model of oxaliplatin-induced neurotoxicity. The antioxidant potential of extract was first evaluated in cell-free models by the thiobarbituric acid-reactive substances assay and nitro blue tetrazolium oxidation test; the ability of H...
February 4, 2017: Zeitschrift Für Naturforschung. C, A Journal of Biosciences
https://www.readbyqxmd.com/read/28156610/decision-of-palliative-chemotherapy-in-late-stage-cancer-the-doctor-patient-relationship-and-the-decision-making-process-as-seen-by-an-oncologist
#13
Marie Pechard, Ivan Krakowski, Christophe Tournigand, Marcel-Louis Viallard
: 48 Background: We conducted a literature review on the administration of palliative chemotherapy in cancer patients at advanced stage. We wondered about ethical tensions encountered by the oncologists during the decision process to meet or not the patients' demand to have access to a palliative chemotherapy at a late stage of the disease. METHODS: We conducted a multicenter, qualitative study of senior oncologists in university hospitals and cancer centers in France, by carrying out interviews with eleven oncologists...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28153339/characterization-of-admission-types-in-medically-hospitalized-patients-prescribed-clozapine
#14
Jonathan G Leung, M Earth Hasassri, Jason N Barreto, Sarah Nelson, Robert J Morgan
BACKGROUND: Clozapine is the antipsychotic of choice for treatment-resistant schizophrenia; however, rigorous monitoring is required to prevent or detect adverse drug events that contribute to morbidity and mortality. In addition to the Food and Drug Administration (FDA) boxed safety warnings specific to clozapine (agranulocytosis, hypotension, seizures, and cardiomyopathy/myocarditis), other adverse events such as pneumonia and gastrointestinal hypomotility have been reported in the literature to result in hospitalization...
November 18, 2016: Psychosomatics
https://www.readbyqxmd.com/read/28152792/use-of-alkylating-chemotherapy-in-high-grade-neuroendocrine-tumours-evaluation-of-real-world-data
#15
Michael Susmoy Sanatani, Stephen Welch, Walter Ilarion Kocha, Sue Richter
: 78 Background: High-grade neuroendocrine tumours (NETs) are believed to have activity to certain alkylating agents, although data are scant. These regimens include streptozotocin (STZ) (used in combination with doxorubicin or 5-fluorouracil) and dacarbazine (DTIC). Current series report variable responses between 6 - 69%. Our objective was to evaluate our real world data to better understand treatment decision-making and clinical outcomes with alkylating agents in advanced high-grade NETs...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28143668/resting-energy-expenditure-in-the-risk-assessment-of-anticancer-treatments
#16
Anne Jouinot, Clara Vazeille, Jean Philippe Durand, Olivier Huillard, Pascaline Boudou-Rouquette, Romain Coriat, Jeanne Chapron, Nathalie Neveux, Jean Pascal De Bandt, Jerome Alexandre, Luc Cynober, Francois Goldwasser
BACKGROUND & AIMS: Alterations of nutritional and performance status (PS) are associated with higher risk of chemotherapy toxicity. Increased resting energy expenditure (REE) is frequent in cancer patients and may contribute to cachexia. We investigated whether abnormal energetic metabolism could predict early acute limiting toxicities (ELT) of anticancer treatments. METHODS: In this observational monocentric study, REE was measured by indirect calorimetry before treatment initiation...
January 19, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28139261/activity-of-bevacizumab-containing-regimens-in-recurrent-low-grade-serous-ovarian-or-peritoneal-cancer-a-single-institution-experience
#17
Heather J Dalton, Nicole D Fleming, Charlotte C Sun, Priya Bhosale, Kathleen M Schmeler, David M Gershenson
OBJECTIVE: The aim of this study was to evaluate the activity of bevacizumab in a cohort of women with recurrent low-grade serous carcinoma of the ovary or peritoneum. METHODS: This single-institution retrospective study assessed all patients at MD Anderson Cancer Center with recurrent low-grade serous ovarian or peritoneal cancer who received bevacizumab from 2007 to 2016. Study endpoints included best response, median progression-free survival, median overall survival, and toxicity...
January 27, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28137855/amh-mis-as-a-contraceptive-that-protects-the-ovarian-reserve-during-chemotherapy
#18
Motohiro Kano, Amanda E Sosulski, LiHua Zhang, Hatice D Saatcioglu, Dan Wang, Nicholas Nagykery, Mary E Sabatini, Guangping Gao, Patricia K Donahoe, David Pépin
The ovarian reserve represents the stock of quiescent primordial follicles in the ovary which is gradually depleted during a woman's reproductive lifespan, resulting in menopause. Müllerian inhibiting substance (MIS) (or anti-Müllerian hormone/AMH), which is produced by granulosa cells of growing follicles, has been proposed as a negative regulator of primordial follicle activation. Here we show that long-term parenteral administration of superphysiological doses of MIS, using either an adeno-associated virus serotype 9 (AAV9) gene therapy vector or recombinant protein, resulted in a complete arrest of folliculogenesis in mice...
January 30, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28133258/-a-rare-case-of-retroperitoneal-metastasis-from-ascending-colon-cancer-that-required-multimodal-treatment
#19
Marie Hanaoka, Shinichi Yamauchi, Akifumi Kikuchi, Michiyo Tokura, Megumi Ishiguro, Toshiaki Ishikawa, Masamichi Yasuno, Hiroyuki Uetake
A patient in his 70's underwent a right hemi-colectomy due to an ascending colon cancer in a previous hospital. The tumor had widely infiltrated the retroperitoneal space(pT3, pN0[0/12], pPM0, pDM0, pRM1, Stage II ). He was referred to our institute 1 month after primary surgery to receive chemotherapy for his residual tumor. Abdominal computed tomography (CT)showed a 24mm tumor in his retroperitoneal space before chemotherapy. After 4 cycles of mFOLFOX6 and panitumumab, the tumor partially responded, and after 7 cycles, he achieved a complete response(CR)...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133237/-malignant-pleural-mesothelioma-with-excessive-inflammation-and-high-level-of-interleukin-6-a-case-report
#20
Tomoya Miura, Satoshi Iida, Takahiro Igaki, Hiroyuki Shiobara, Ryou Matsumoto, Katsutaka Mitachi, Teppei Miyakawa, Yoshiaki Ohata, Katsumasa Saitou, Takumi Irie, Shigeru Yamazaki
Malignant mesothelioma is a rare aggressive solid tumor that is invariably incurable. A 23-year-old female patient with ascites, anemia, and high levels of ferritin and CRP was diagnosed with pleural mesothelioma by exploratory laparotomy. She remained asymptomatic, but 7 years later, she developed intractable diarrhea and fever. Systematic chemotherapy with both cisplatin and pemetrexed was administered. However, the treatment was discontinued due to side effects, after which time the diarrhea, ascites, and fever became progressively more severe...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
31212
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"